期刊文献+

急性冠状动脉综合征患者经皮冠状动脉介入术后无复流现象的危险因素及预后 被引量:6

Risk factors and prognosis of no-reflow phenomenon in patients with acute coronary syndrome after PCI
暂未订购
导出
摘要 目的分析经皮冠状动脉介入治疗(PCI)后冠状动脉无复流现象发生的危险因素和预后。方法回顾性分析因急性冠状动脉综合征入我院行PCI治疗的患者524例中有较完整随访资料的427例,PCI支架置入即刻在无影响血流的血栓、栓塞、夹层、痉挛情况下,冠状动脉造影前向血流TIMI≤2级为无复流,TIMI 3级为正常血流。利用Excel随机函数表,从393例急诊PCI冠状动脉前向血流恢复正常的患者中随机抽取70例,为对照组。结果冠状动脉无复流患者34例,无复流组心肌梗死和糖尿病比例明显高于对照组,且胰岛素水平、白细胞总数和中性粒细胞总数也明显高于对照组。院内和院外不良事件发生率无复流组明显高于对照组,左心室射血分数较前明显减低,而左心室舒张末内径较前明显增大。结论无复流受既往糖尿病、胰岛素及白细胞水平的影响,可使住院期间和院外不良事件明显增加,是心肌继续缺血、心室重构和心功能恢复障碍的预测因子,也是心肌和微血管损伤的标志。 Objective To investigate the risk factors and prognosis of no-reflow phenomenon in patients after pereutaneous coronary intervention (PCI). Methods Retrospectively analyzed 524 patients with acute coronary syndrome after PCI of which 427 patients had detailed record. Angiographic no-reflow phenomenon was designated as TIMI≤2 flow without mechanical obstruction of embolism, thrombus, dissection and spasm. Normal flow designated as TIMI 3 flow. Using random count table of Excel, 70 patients were randomized from 393 patients with coronary flow TIMI 3 after PCI as the control normal flow group. Results The no reflow group enrolled 34 patients. Compared with the normal flow group, their incidence of AMI and diabetes, the blood insulin level and mean leukocyte count were significantly higher. The incidence of MACE in and out of hospital was higher in the no reflow group than the normal flow group. Within the no reflow group, the EF decreased while the LVEDD increased significantly PCI. Conduslon History of diabetes, blood insulin levd and leukocyte count may be the risk factors of no-reflow. On the other hand, the no reflow phenomenon maybe a prognostic factor of MACE, ventricular remodeling and heart function for patients after PCI. Prognosis
出处 《中国介入心脏病学杂志》 2006年第1期34-36,共3页 Chinese Journal of Interventional Cardiology
关键词 血管成形术 经腔 经皮冠状动脉 急性冠状动脉综合征 预后 Angioplasty, transluminal , percutaneous coronary Acute coronary syndrome
  • 相关文献

参考文献6

  • 1Resnic FS,Wainstein M,Lee MK,et al.No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention.Am Heart J,2003,145:9-11.
  • 2Gin S,Mitchel J F,Hirst JA,et al.Synergy between intracoronary stenting and abciximab in improving angiographic and clinical outcomes of primary angioplasty in acute myocardial infarction.Am J Cardial,2000,86:269-274.
  • 3Wainstein M,Frederic F,Lee M,et al.Lack of clinical efficacy of pharmacologic treatment of the no-reflow phenomenon despite significant angiographic improvement.J Am Coll Cardiol,2001,37:83-86.
  • 4Iwakura K,Ito H,Ikushima M,et al.Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction.J Am Coll Cardiol,2003,41:1-7.
  • 5Kojima S,Sakamoto T,Ishihara M.The white blood cell count is an independent predictor of no-reflow and mortality following acute myocardial infarction in the coronary interventional era.Ann Med,2004,36:153-160.
  • 6Morishima I,Sone T,Okumura K,et al.Aniographic no-reflow phenomenon as a predictor of adverse long term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction.J Am Coll Cardiol,2000,36:1202-1209.

同被引文献38

  • 1冯庚.急性心肌梗死的现场溶栓和介入治疗[J].中国全科医学,2005,8(1):62-62. 被引量:6
  • 2高润霖.从急性心肌梗死治疗指南看再灌注治疗策略的选择[J].中华心血管病杂志,2005,33(11):1061-1064. 被引量:74
  • 3韩艳丽,李继福,陈玉国,李贵双,王营,许维亮.经皮冠状动脉介入治疗时无再流现象的处理[J].中国介入心脏病学杂志,2005,13(6):383-385. 被引量:2
  • 4杨跃进,赵京林.急性心肌梗死再灌注治疗的现代观念[J].中国实用内科杂志,2006,26(8):1124-1128. 被引量:18
  • 5陈国伟 郑宗锷.现代心脏内科学[M].湖南科学技术出版社,1996.908-921.
  • 6[1]MOSES J W,LEON M B,POPMA J J,et al.Sirolimuseluting stents versus standard stents in patients with stenosis in a native coronaryartery[J].N Engl J Med,2003,349(14):1315-1323.
  • 7[2]LEMOS P A,SAIA F,HOFMA S H,et al.Short-and long-term clinical benefit of sirolimus-eluting stnets compared to conventional bare stents for patients with acute myocardial infarction[J].J Am Coll Cardiol,2004,43 (4):704-708.
  • 8[3]GIRl S,MITCHEL J F,HIRST J A,et al.Synergy between intracoronary stenting and abciximab in improving angiographic and clinical outcomes of primary angioplasty in acute myocardial infarction[J].Am J Cardial,2000,86(3):269-274.
  • 9[4]MCFADDEN E P,STABILE E,REGAR E,et al.Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy[J].Lancet,2004,364 (9444):519-1521.
  • 10[5]FARB A,BURKE A P,KOLODGIE F D,et al.Pathological mechanisms of fatal late coronary stent thromosis in humans.Circulation,2003,108(14):1701-1706.

引证文献6

二级引证文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部